|
Dec 20
|
Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study
|
|
Dec 19
|
Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
|
|
Sep 5
|
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Jul 30
|
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
|
|
May 7
|
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
|
|
Mar 21
|
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update
|
|
Mar 4
|
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva
|
|
Nov 14
|
Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update
|